Search Thermo Fisher Scientific
Invitrogen
图: 1 / 3
Recombinant rabbit monoclonal antibodies are produced using in vitro expression systems. The expression systems are developed by cloning in the specific antibody DNA sequences from immunoreactive rabbits. Then, individual clones are screened to select the best candidates for production. The advantages of using recombinant rabbit monoclonal antibodies include: better specificity and sensitivity, lot-to-lot consistency, animal origin-free formulations, and broader immunoreactivity to diverse targets due to larger rabbit immune repertoire.
KDR (FLK1, VEGFR2) is a type III receptor tyrosine kinase. It binds vascular endothelial growth factor with high affinity in vitro, and is expressed early in development by endothelial cell precursors. FLK1 (VEGF Receptor 2) encodes one of the two receptors of the VEGF. This receptor, known as kinase insert domain receptor, is a type III receptor tyrosine kinase. The signalling and trafficking of this receptor are regulated by multiple factors, including Rab GTPase, P2Y purine nucleotide receptor, integrin alphaVbeta3, T-cell protein tyrosine phosphatase, etc. Mutations of FLK1 (VEGF Receptor 2) are implicated in infantile capillary hemangiomas.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
蛋白别名: CD309; CD309 antigen; Fetal liver kinase 1; fetal liver kinase-1; FLK-1; KDR; Kinase insert domain receptor; kinase insert domain receptor (a type III receptor tyrosine kinase); Protein-tyrosine kinase receptor flk-1; sCD309; soluble CD309; soluble VEGFR 2; soluble VEGFR2; tyrosine kinase growth factor receptor; Vascular endothelial growth factor receptor 2; VEGF R2; VEGFR-2
基因别名: CD309; FLK1; KDR; VEGFR; VEGFR2
UniProt ID: (Human) P35968
Entrez Gene ID: (Human) 3791